Tianjin Medical University Cancer Institute and Hospital clinical trials
Listed in the registry as: University, hospital or other organization.
The registry lists 490 studies whose lead sponsor is Tianjin Medical University Cancer Institute and Hospital. 289 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 23, 2026.
Keep track of what changes. Save the Tianjin Medical University Cancer Institute and Hospital studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesStatus
Focus areas
Conditions Tianjin Medical University Cancer Institute and Hospital leads ten or more studies in, by study count. A broader condition is left out when almost all its studies are already in a narrower one listed here.
Studies
Recruiting first, then most recently updated. Showing 50 of 490. Browse all 490 →
- Stratified Treatment in Unresectable Locally Advanced ESCC Without Progression After Chemoimmunotherapy Induction Plus CCRT: Toripalimab Consolidation vs observation--a Prospective, Randomized, Controlled Phase III Multicenter StudyRecruitingNCT07246330Phase 3
- Effect of Low-Dose Esketamine Combined With Dexmedetomidine on the Incidence of Chronic Postsurgical Pain in Patients Undergoing Pancreatic SurgeryNot yet recruitingNCT07888413Phase 4
- QL1706-Based Therapy Post-PD-1/L1 Failure in Advanced Endometrial CancerRecruitingNCT06917092Phase 2
- dCRT vs. Surgery in Resectable ESCC Patients Achieving cCR/PR After Induction ChemoimmunotherapyRecruitingNCT07162506Phase 2
- Fecal Microbiota Transplantation Combined With QL1706 Plus Bevacizumab for Advanced HCCNot yet recruitingNCT07847671Phase 2
- Umbilical Cord Blood Infusion to Promote Hematopoietic and Immune Reconstitution in Children With Relapsed or Refractory Malignant Solid TumorsNot yet recruitingNCT07866534Not applicable
- Fecal Microbiota Transplantation Combined With NALIRIFOX Plus Serplulimab as First-line Treatment for Advanced or Metastatic Pancreatic Ductal Adenocarcinoma.Not yet recruitingNCT07854977Phase 2
- Phase II Study of Chidamide-Dinutuximab Beta-Irinotecan-Temozolomide for Refractory/Relapsed Neuroblastoma in ChildrenRecruitingNCT07318831Phase 2
- FMT Plus SHR-1701 With Nab-Paclitaxel/Gemcitabine as First-Line Treatment for Locally Advanced or Metastatic Pancreatic Ductal AdenocarcinomaNot yet recruitingNCT07845565Phase 2
- Neoadjuvant Therapy for Early Triple-Negative Breast Cancer: A Response-Guided Approach Using Iparomlimab and Tuvonralimab Injection in Combination With ChemotherapyRecruitingNCT07372079Phase 2
- Biomarker Validation for Treatment Efficacy and Recurrence Prediction in Hepatocellular CarcinomaRecruitingNCT07840092
- Efficacy and Safety of Anrikefon Injection for the Treatment of Postoperative Pain in Patients Undergoing Totally Laparoscopic Radical Distal GastrectomyRecruitingNCT07330063Phase 2
- Hypofractionated Radiotherapy After Breast Reconstruction for Breast CancerNot yet recruitingNCT07831889Not applicable
- Albumin-bound Paclitaxel (Ⅱ)-Combined Regimens for Pancreatic CancerNot yet recruitingNCT07828756Phase 2
- Dalpiciclib Plus Toremifene for First-line Advanced HR Positive and HER2 Negative Breast CancerRecruitingNCT06495515Phase 2
- Efficacy and Safety of Anrikefon Injection for the Treatment of Postoperative Pain in Patients Undergoing Laparoscopic HepatectomyNot yet recruitingNCT07826806Phase 2
- Five-Element Music Therapy for Psychological Distress in Pancreatic Cancer ChemotherapyNot yet recruitingNCT07796906Not applicable
- Risk-Stratified Management of Inavolisib-Induced Hyperglycemia and Patient AdherenceRecruitingNCT07817056
- SBRT Combined With Reduced-Dose Anthracycline Chemotherapy and Toripalimab as Neoadjuvant Therapy for Localized High-Risk Undifferentiated Pleomorphic SarcomaNot yet recruitingNCT07817095Phase 2
- Phase II Study of SHR-A1811 for Ultra-Low HER2 Advanced Breast CancerRecruitingNCT07817082Phase 2
- HDR Endorectal Brachytherapy With 3D-Printed Guidance and Local Shielding for Rectal Cancer Organ PreservationRecruitingNCT07786493Not applicable
- Efficacy and Safety of Stereotactic Body Radiation Therapy for Spinal Metastases With Bilsky Grade 1c-3RecruitingNCT07809672Not applicable
- Phase II Study of Trastuzumab Rezetecan Combined With Retlirafusp Alfa With or Without CAPOX as Perioperative Therapy for Resectable Locally Advanced Gastric/Gastroesophageal Junction AdenocarcinomaNot yet recruitingNCT07802288Phase 2
- Iparomlimab/Tuvonralimab Plus SBRT and Lenvatinib for Perioperative Treatment of Potentially Resectable Intermediate-Stage HCCRecruitingNCT07801287Phase 2
- Postoperative Edge (RapidArc) Stereotactic Body Radiotherapy for Spinal MetastasesRecruitingNCT07801274
- IRE After Chemotherapy for Locally Advanced Pancreatic CancerRecruitingNCT07799935Not applicable
- IRE After Targeted Immunotherapy in HCC With Portal Vein Tumor ThrombusRecruitingNCT07799922Not applicable
- HCCANANO-HOPE1: IRE After Chemotherapy for Locally Advanced Unresectable Perihilar CholangiocarcinomaRecruitingNCT07795619Not applicable
- Baduanjin for Quality of Life in Pancreatic Cancer ChemotherapyNot yet recruitingNCT07791550Not applicable
- An Exploratory Study on the Efficacy and Safety of Enlonstobart Combined With Concurrent Radiotherapy and Chemotherapy Following Induction Therapy With Enlonstobart Plus Chemotherapy in Patients With Locally Advanced Cervical Cancer.RecruitingNCT07776821Phase 4
- A Single-Arm Phase Ⅱ Study of Fluzoparib Maintenance in Platinum-sensitive Advanced Triple-Negative Breast CanceRecruitingNCT07321015Phase 2
- Adebrelimab Combined With Dalpiciclib Isethionate Plus Chemotherapy for Neoadjuvant Treatment of Locally Advanced Head and Neck Squamous Cell CarcinomaNot yet recruitingNCT07778732Phase 2
- A Prospective Phase II Clinical Trial Evaluating the Efficacy and Safety of Adebrelimab in Combination With Trastuzumab Rezetecan for Patients With Stage III Unresectable HER2-Positive NSCLCNot yet recruitingNCT07778745Phase 2
- Thiotepa Administration Via Ommaya Reservoir for Leptomeningeal Metastases in Non-Small Cell Lung Cancer Resistant to EGFR-TKI.Not yet recruitingNCT07778940Phase 2
- A Study on the Efficacy of Different Doses of Oryz-Aspergillus Enzyme And Pancreatin Tablet in Treating Pancreatic Exocrine Insufficiency After Gastrointestinal SurgeryNot yet recruitingNCT07751367Not applicable
- A Study of Neoadjuvant Tislelizumab Plus Lenvatinib in Resectable HCC at High Risk of RecurrenceRecruitingNCT07475026Phase 3
- Glofitamab Combination With Chidamide in Patients With Recurrent/Refractory DLBCLRecruitingNCT06570447Phase 2
- A Single-arm, Multi-center, Phase II Exploratory Clinical Study to Evaluate the Efficacy and Safety of Trilaciclib in Preventing Myelosuppression Caused by Topoisomerase I Inhibitor Type ADC DrugsNot yet recruitingNCT07736001Not applicable
- To Explore a Single-arm Phase II Study on Intestinal Microbiota Transplantation Combined With Neoadjuvant Immunotherapy and Chemoradiotherapy for Locally Advanced Rectal Cancer Under MSS/pMMRNot yet recruitingNCT07738042Not applicable
- Study on the Combined Treatment of Hepatocellular Carcinoma With Envafolimab, Suvemcitug and HAIC ConversionNot yet recruitingNCT07738055Not applicable
- CRP Regimen in Treating Elderly Patients With Previously Untreated Double-Positive DLBCLRecruitingNCT07397832Phase 2
- Comparing ICI Followed By CCRT And CCRT Followed By Immunotherapy In Unresectable LA-ESCCRecruitingNCT07733830Phase 2
- A Phase II Exploratory Study of Sacituzumab Tirumotecan Combined With Envafolimab for TROP2-Positive Advanced Biliary Tract Cancers Previously Treated With First-Line Immunotherapy Combined With Chemotherapy.Not yet recruitingNCT07729033Phase 2
- Study on Sequential Cryoablation, Relaforp Alpha, and Chemotherapy for Bile Duct TumorsRecruitingNCT07726446Phase 2
- Multi-Cohort Study of Zeprumetostat Combinations for Relapsed/Refractory PTCLNot yet recruitingNCT07724782Phase 1/2
- Fosrolapitant Combined With Palonosetron to Prevent Trastuzumab Rezetecan Related CINVRecruitingNCT07726433Phase 2
- Butyrate Yogurt for Cancer ConstipationNot yet recruitingNCT07723729Phase 2
- Tislelizumab Combined With Chemotherapy for Different Cycles of Neoadjuvant Therapy for Locally Advanced Resectable Squamous Cell Carcinoma of the Head and Neck (NeoTempo)RecruitingNCT07147426Phase 2
- Early Response-guided Sequential Radiotherapy After Chemoimmunotherapy for Locally Advanced Esophageal Squamous Cell CarcinomaNot yet recruitingNCT07721103Phase 2
- AK112 Combination Therapy as First Line Treatment for Metastatic Digestive System Neuroendocrine CancerNot yet recruitingNCT07712094Phase 2